SSA
KLRS

Schonfeld Strategic Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-578
Closed -$366K – 1936
2020
Q3 		$366K Buy
+578
New +$395K 0.01% 1019

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Schonfeld Strategic Advisors's KLRS Position: Q4 2020 in Review

Schonfeld Strategic Advisors sold out of Kalaris Therapeutics (KLRS) in Q4 2020, closing a stake of 578 shares — an estimated $366K sold.

Schonfeld Strategic Advisors first reported a position in KLRS in Q3 2020 and held it in 1 quarter. The position peaked at $366K in Q3 2020. 71 funds tracked by Wall St. Rank hold KLRS as of Q4 2020.

  • Schonfeld Strategic Advisors reported no remaining Kalaris Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 578 Kalaris Therapeutics shares in Q4 2020, an estimated $366K.
  • Schonfeld Strategic Advisors first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Kalaris Therapeutics position peaked at $366K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.